A new approach to treating malignant brain tumors has been discovered, with chemotherapy alone proven to be just as effective as traditional radiation therapy. The study identified a key gene mutation called IDH1 that predicts a better prognosis for patients, regardless of treatment.
Researchers at Weizmann Institute discovered a new protein partnership between TrkA and CCM2 that leads to pediatric tumor regression. This finding may lead to the development of drugs that induce tumor regression. The study found that TrkA and CCM2 are always expressed together in tumors with high regression rates.
Researchers have discovered a small peptide that stops lung cancer tumors from growing by inhibiting blood vessel formation. The study showed significant reduction in tumor size and fewer blood vessels compared to untreated animals.
Researchers have developed a targeted cancer treatment using nanomaterials that selectively kills brain cancer cells while leaving healthy cells unaffected. The therapy uses titanium dioxide nanoparticles bonded to biological material and targets specific cell surface receptors on cancer cells.
A protein called Huwe1 normally functions to eliminate unnecessary proteins, acting as a tumor suppressor in brain cancer. Deregulation of Huwe1 function is involved in tumor development and may be an important factor in the development of brain cancer.
Researchers found that STAT3 inhibits the growth and self-renewal of glioblastoma stem cells, suggesting a promising target for cancer therapy. The study demonstrates the potential of STAT3 inhibitors to stop tumor formation and offers a new approach to treating this devastating brain cancer.
Patients who received radiotherapy for low-grade glioma brain tumors showed significant cognitive decline compared to those who did not receive treatment. The study found that attentional functioning, executive functioning, and information processing speed were lower in patients given radiotherapy. Deferring treatment or using modern r...
Researchers at the University of Washington developed nanoparticles that cross the blood-brain barrier, illuminating brain tumors and improving MRI and optical imaging. This breakthrough could lead to more precise surgery and earlier cancer detection.
UCLA researchers developed a new way to scan brain tumors and predict which ones will respond to the drug Avastin before treatment. By linking high water movement in tumors to positive drug response, they predicted with 70 percent accuracy which patients' tumors were the least likely to grow six months after therapy.
The Peninsula College of Medicine and Dentistry has received a grant to study the role of brain tumors in deafness and develop non-invasive therapies. The research aims to identify how tumors grow and cause hearing damage, and test drug-based treatments.
Researchers at Cedars-Sinai Medical Center have isolated stem-like cells from benign pituitary tumors and shown they can generate new tumors in laboratory mice. The study supports the cancer stem cell hypothesis, suggesting similar mechanisms may be involved in malignant and benign tumor formation.
Researchers discovered that glioma cells use microglia, the brain's immune cells, to grow and expand rapidly. By manipulating microglial cells' receptors, gliomas can clear the way for further growth.
A recent study published in JAMA Network has found a network of altered genes that appear to play a crucial role in the development and progression of brain tumors. The researchers identified seven landscape genes that are associated with patient prognosis and survival.
A network of 31 mutated genes has been identified as the driving force behind glioblastoma growth. Annexin A7, a vital guard gene, is lost in most cases, allowing tumors to flourish. The discovery offers new therapeutic targets and potentially extends patient survival.
A new medical treatment using bevacizumab has successfully improved hearing and alleviated symptoms in patients with neurofibromatosis type 2 (NF2). The study shrank characteristic tumors, including vestibular schwannomas on the balance and hearing nerves.
Scientists at Virginia Tech have developed a hands-off process for filling fullerenes with radio-active material, increasing control of radiation therapy. The new material allows for targeted localization and potentially fewer side effects in brain tumor treatment.
Researchers at Mayo Clinic and University of California San Francisco have discovered a connection between DNA alterations on human chromosome 9 and glioblastoma. The study found that individuals with specific single nucleotide polymorphisms (SNPs) are 50% more likely to develop the aggressive brain cancer.
Researchers have identified a fruit fly tumor suppressor gene, PP2A, that can prevent brain tumors from forming. The study suggests that the protein's counterpart in mammals may also play a crucial role in regulating neural stem cell divisions and controlling tumor development.
Researchers design a minimally invasive system combining ultrasound and chemotherapy to target brain tumors without surgery or radiation. The approach aims to provide real-time imaging and localized temperature increases to melt liposome shells and release chemotherapy directly to the tumor.
PTEN-deficient cells have defective checkpoints that allow them to bypass DNA repair and continue growing despite radiation damage. Researchers found that correcting faulty checkpoint processes could increase radiation sensitivity in tumors with PTEN mutations.
A University of Cincinnati study found that performing stereotactic needle biopsies in eloquent areas of the brain, associated with language or other critical functions, carries no greater risk than in non-eloquent areas. The study compared complication rates between functional and non-functional brain regions.
A new MRI test involving breathing oxygen may help oncologists determine the best treatment for some cancer patients. The BOLD technique detects oxygen levels in tumors without invasive procedures, providing insight into how tumors behave and what treatments might be effective.
A UCF researcher is developing a computer program to analyze brain scans and automatically measure tumor size in 3D. The program has shown up to 90% accuracy compared to human analysis and could help determine treatment plans for patients.
Researchers created a mathematical formula that incorporated equations describing tumor evolution and growth, predicting oxygen consumption rates and cell growth. The computational model was validated with human brain tumor samples and successfully mimicked natural biological tumors.
A new mathematical model developed at the University of Texas Health Science Center at Houston suggests that tumor growth and invasion can be predicted using biophysical laws. The model, which links molecular and cellular properties to tumor behavior, consistently reproduced patterns of tumor invasion observed in experiments and patien...
Researchers found a biological link between tumors and negative mood changes in animal models, suggesting that tumor-induced molecules may be responsible for depression. The study also showed that disruptions in gene expression and stress hormone production are associated with tumor development.
Co-transplanting bone marrow stem cells with embryonic stem cells eliminates tumor formation in spinal cord injury (SCI) laboratory animals. The study suggests that BMSCs induce differentiation of undifferentiated ES cells into a neuronal lineage, resulting in suppression of tumor growth.
A new MRI technique accurately predicts specific genetic mutations in human brain tumors, a breakthrough that could lead to better diagnosis and treatment of glioblastoma. By measuring blood flow to the tumor, researchers can identify patients with high-risk mutations that require targeted therapies.
Researchers found that brain metastases subvert astrocytes, tricking them into protecting tumors and resisting chemotherapy. Surgery is effective when tumor removal is done intact, reducing the risk of cancer spreading to the spinal fluid.
Researchers at the University of Michigan developed a method to analyze changes in a tumor's blood flow and volume, allowing for early prediction of patient survival. The 'parametric response map' approach showed promising results in predicting treatment response earlier than traditional methods.
Researchers at USC have identified a new compound that targets both tumor cells and surrounding blood vessels, potentially leading to more effective treatment options for brain tumors. The study found that the compound reduced tumor growth and blood vessel density in animal studies.
TGen researchers have identified a potential therapeutic target for glioblastoma multiforme (GBM) by regulating the actions of NHERF-1, a gene implicated in tumor cell migration and division. Depletion of NHERF-1 stops GBM cell migration, suggesting its role in tumor invasion.
A team of scientists has discovered a compound that can block the growth of brain tumors by reversing the effects of an altered enzyme. The mutation in the IDH1 gene impairs the body's ability to control a protein that promotes tumor growth, but adding a modified form of alpha-KG can restore this balance.
Researchers at UNC School of Medicine have identified a compound that could treat secondary glioblastoma multiforme (GBM), a type of brain tumor. By replenishing α-ketoglutarate, they reversed the effects of IDH1 gene mutation, which contributes to tumor growth.
The study found that treatment with cediranib reduced edema and improved survival in mice with glioblastoma tumors. Mice receiving the drug lived significantly longer than controls, despite continued tumor growth.
Scientists at The University of Nottingham have uncovered a vital new biological clue that could lead to more effective treatments for CNS PNETs, a type of brain tumour predominantly occurring in children. The research found that WNT pathway activation is linked to patient survival and may represent an important new target for treatment.
Researchers have discovered new tumor markers that can accurately predict the course of disease and treatment response in childhood brain tumors. These markers, found in medulloblastoma DNA, can help adjust therapy intensity to reduce damage and secondary malignancies.
Researchers at Bonn University discovered a critical improvement in treating glioblastoma, the most aggressive and common brain tumor. The combination of two drugs increased average survival time to 23 months, with some patients surviving over four years. Further investigations are needed to optimize this therapy.
A rare case of a boy with Ataxia Telangiectasia developed abnormal growths in his brain and spinal cord four years after receiving human fetal stem cell therapy. The tumors were found to be benign neural tumors that could not have arisen from the patient's own tissues, highlighting the need for caution in stem cell therapy.
Researchers at University of Cincinnati discovered that estrogen receptors are present in medulloblastoma, the most common type of pediatric brain tumor. This finding suggests that anti-estrogen drug treatments may be beneficial in limiting tumor progression and improving patient outcomes.
Researchers at the Salk Institute used fruit flies as a model to study gliomas, the most common malignant brain tumors. They found that activating specific signaling pathways in the fly brains resulted in tumor-like growths, mimicking human disease.
A clinical decision model using MR spectroscopy can help patients avoid unnecessary biopsies and treatments by identifying whether a new lesion is due to a recurrent tumor or post-radiation changes. The technique analyzes ratios of three metabolites, including choline, creatine, and NAA, to determine the likelihood of a recurrent tumor.
A gene variant has been linked to an increased risk of developing brain tumors at a younger age, with 20.6% of young people with glioblastoma multiforme having the Pro/Pro variant of the TP53 gene compared to 5.9% of healthy participants.
Researchers at Cedars-Sinai Medical Center developed a gene therapeutic approach that results in tumor regression and long-term survival. The approach uses proteins to draw dendritic cells into the brain tumors, stimulate an anti-tumor response, and increase survival time by six months.
Researchers have identified a mechanism for an effective immune response to brain tumors by combining immunotherapy and strategies to kill tumor cells. The study suggests that this combination may provide effective treatment for glioblastoma multiforme, the most aggressive form of brain cancer.
Researchers from Boston College and Washington University School of Medicine report new evidence supporting the original Warburg Theory of Cancer. Abnormalities in cardiolipin content were found in all types of brain tumors, closely associated with significant reductions in energy-generating activities.
Researchers at the Salk Institute have developed a new glioblastoma mouse model that closely resembles human brain tumors. The model uses modified viruses to shuttle cancer-causing oncogenes into adult mice, allowing scientists to study the development and progression of glioblastoma.
Researchers at UC Davis Cancer Center have discovered a molecule called LXY1 that targets glioblastoma, a deadly form of brain cancer. The molecule binds to alpha-3 integrin on cancer cells, allowing for direct delivery of treatments and sparing normal tissues.
GUMC researchers discovered PTPRD gene inactivation in melanoma and glioblastoma, a potential tumor suppressor role. The findings suggest a wide applicability of PTPRD in various cancers, paving the way for novel therapy.
Patients with low-grade gliomas who underwent aggressive surgeries were free of tumor recurrence an average of 15 years after diagnosis. Radiation therapy significantly extended their survival time, with patients living up to six years without tumor recurrence.
Glioblastoma cells release exosomes containing RNA and proteins that promote tumor growth, but also carry data that can be used to guide targeted therapy. The study identified factors in these exosomes that could be used as biomarkers to monitor treatment response.
A new study by Tel Aviv University and the University of Utah found a significant link between brain cancer and family history. Researchers discovered that a four-fold increase in risk exists for individuals with a family history of brain tumors, highlighting genetic predispositions.
Researchers identified a molecular mechanism involved in the development of cancer stem cells, which can lead to malignant brain tumors. Targeting this signaling pathway with gene therapy may prevent tumor recurrence.
Recent studies suggest a possible link between long-term cell phone use and increased risk of brain tumors, prompting a call for collaborative research initiatives. Scientists emphasize the need for definitive evidence to determine the risks associated with electromagnetic field exposure from cell phones.
A new research project will develop and test new ways of scanning childhood tumours in depth, giving doctors a more detailed diagnosis and better indication of how to treat the tumour. This project is part of a nationwide investment of £50m to establish cancer imaging centres and research programmes.
Researchers at Massachusetts General Hospital have discovered a new approach to gene therapy that uses normal brain tissue to create a 'zone of resistance' against brain tumor growth. By delivering a cancer-fighting gene to the surrounding tissue, tumors can be suppressed and eventually eliminated.
Researchers developed a novel technique for detecting tumor lymphangiogenesis in rabbits, using percutaneous hepatic injection of ultrasound contrast material. The method combines percutaneous transhepatic lymphosonography (PTL) with contrast-enhanced ultrasonographic imaging to improve diagnostic ability for liver cancer.
Dr. Sanjay Kumar, a UC Berkeley bioengineer, has been awarded a $1.5 million NIH New Innovator Award to investigate the role of mechanical forces in human health and disease. His research aims to understand how cells process biophysical cues, which could lead to the development of new chemotherapeutic drugs for brain tumors.
The study identifies frequently mutated genes, including ERBB2 and NF1, which were previously underestimated in their role in glioblastoma. The analysis also provides a wide view of how cell pathways are altered during the initiation and growth of glioblastoma, offering insights into strategies to diagnose and treat the disease.
Researchers at Medical College of Wisconsin report promising results using drugs to inhibit angiogenesis in rat models of glioblastoma, a deadly brain tumor. Tumor size was reduced by 50-70% and survival time increased by 5-7 days